Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 8,064 Shares of Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00. Following the transaction, the insider now owns 1,255,730 shares in the company, valued at approximately $4,395,055. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Down 0.9 %

Shares of Genelux stock traded down $0.03 on Wednesday, reaching $3.45. 137,205 shares of the company traded hands, compared to its average volume of 125,442. Genelux Co. has a 52 week low of $3.26 and a 52 week high of $40.98. The company has a 50 day moving average of $5.95 and a 200 day moving average of $11.00.

Genelux (NASDAQ:GNLX) last posted its earnings results on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). As a group, equities analysts predict that Genelux Co. will post -0.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GNLX shares. Benchmark reiterated a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd. HC Wainwright dropped their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd.

Hedge Funds Weigh In On Genelux

Several institutional investors and hedge funds have recently made changes to their positions in the business. Woodward Diversified Capital LLC grew its holdings in Genelux by 2,326.2% in the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after acquiring an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. lifted its position in Genelux by 1,660.1% during the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after acquiring an additional 925,258 shares during the period. Provident Wealth Management LLC purchased a new position in Genelux during the 3rd quarter valued at about $8,211,000. Bank of New York Mellon Corp lifted its position in Genelux by 476.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock valued at $1,321,000 after acquiring an additional 44,584 shares during the period. Finally, AMG National Trust Bank purchased a new position in Genelux during the 3rd quarter valued at about $1,233,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.